Editorial
To Palivizumab or not to Palivizumab – that is the question

https://doi.org/10.1016/j.prrv.2012.12.004Get rights and content

References (8)

  • M.P. Frogel et al.

    A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis

    Journal of Managed Care Pharmacy: JMCP

    (2010)
  • Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory...
  • B. Resch et al.

    Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria

    The Pediatric Infectious Disease Journal

    (2012)
  • D. Wang et al.

    Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses

    Health Technology Assessment

    (2011)
There are more references available in the full text version of this article.
View full text